Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 62 |
| Active Pipeline (Recruiting Now) | 14 (7) |
| Completed vs Stopped Early | 42 / 6 (9.7%) |
| Median Closed Actual Enrollment | 879 participants |
| Physical Hospital Site Disclosure | 99.9% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Velocity Clinical Research (Meridian) | Meridian, ID | 13 |
| Velocity Clinical Research (Cincinnati) | Cincinnati, OH | 11 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07496450 | A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | Phase III | ACTIVE NOT RECRUITING |
| NCT06067230 | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | Phase III | COMPLETED |
| NCT05249829 | A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19 | Phase II/III | COMPLETED |
| NCT05415462 | A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | Phase III | COMPLETED |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Moderna across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the ModernaTX Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.